1. "General Medicine Services"
Formats
  1. Journal Article (305)
  2. Meeting Abstract (203)
  3. Review (20)
  4. Book Section (15)
  5. Editorial (14)
  6. Research Letter (4)
  7. Conference Paper (3)
  8. Correspondence (3)
  9. Miscellaneous (2)
  10. Guidelines (1)
Groups
  1. General Medicine Services (570)
  2. Survivorship Research (366)
  3. General Internal Medicine (311)
  4. Department of Medicine (269)
  5. Population Sciences Research Program (199)
  6. Solid Tumor Oncology Division (150)

More Groups

People
  1. Deborah Korenstein (129)
  2. Jeffrey Groeger (91)
  3. Emily Tonorezos (83)
  4. Alicia Latham (58)
  5. Zsofia Stadler (56)
  6. Kenneth Offit (47)

More People

Years
  1. 2025 (7)
  2. 2024 (23)
  3. 2023 (42)
  4. 2022 (49)
  5. 2021 (50)
  6. 2020 (66)

More Years

Publications
  1. Journal of Clinical Oncology (103)
  2. Blood (31)
  3. Journal of General Internal Medicine (25)
  4. Critical Care Medicine (24)
  5. JAMA Internal Medicine (17)
  6. Cancer (16)

More Publications

Publishers
  1. American Society of Clinical Oncology (117)
  2. Springer (59)
  3. Lippincott Williams & Wilkins (43)
  4. Elsevier Inc. (40)
  5. American Medical Association (34)
  6. American Society of Hematology (33)

More Publishers

Results (570)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Germline pathogenic variants and genetic counseling by ancestry in patients with epithelial ovarian cancer
    Journal Article

    Sia, T. Y.; Maio, A.; Kemel, Y. M.; Arora, K. S.; Gordhandas, S. B.; Kahn, R. M.; Salo-Mullen, E. E.; Sheehan, M. A.; Tejada, P. R.; Bandlamudi, C.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Prevalence and clinical implications of mismatch repair-proficient colorectal cancer in patients with Lynch syndrome
    Journal Article

    Ranganathan, M.; Sacca, R. E.; Trottier, M.; Maio, A.; Kemel, Y.; Salo-Mullen, E.; Catchings, A.; Kane, S.; Wang, C.; Ravichandran, V.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating tumor-intrinsic and patient-specific mechanisms of resistance to teclistamab in anti-BCMA exposed and naïve multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I. S.; Wang, A.; Zhu, M.; Patel, D.; Tan, C.; Hultcrantz, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical outcomes associated with del(17p) in newly diagnosed multiple myeloma treated with triplet and daratumumab-based quadruplet induction regimens
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Barriers to early detection: Insurance denials for breast MRI screening in women with germline BRCA1/2
    Meeting Abstract

    Gordhandas, S.; Yen, T. T.; Ingber, S.; Kahn, R.; Kayani, S.; Taffuri, A.; Sokolowski, S.; Martinez, D.; Garcia, P.; Mullangi, S.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save